Tumor cells, along with other components of the TME, often express ligands for these checkpoints: CD80 for CTLA-4 and PD-L1 for PD-1, which helps tumors evade the immune system by suppressing T cell-mediated antitumor activity [97,98]. This evidence concerns the gene PDCD1 and neoplasm.